Briacell Therap (NASDAQ:BCTX) Releases Earnings Results

Posted by Joseph Casey on Jun 9th, 2026

Briacell Therap (NASDAQ:BCTX – Get Free Report) released its earnings results on Tuesday. The company reported ($0.99) EPS for the quarter, Zacks reports.

Briacell Therap Price Performance

BCTX traded down $0.02 on Tuesday, reaching $3.07. 301,364 shares of the company’s stock were exchanged, compared to its average volume of 373,176. The stock has a market cap of $26.71 million, a PE ratio of -0.13 and a beta of 1.21. Briacell Therap has a twelve month low of $2.93 and a twelve month high of $36.00. The stock’s fifty day moving average price is $3.91 and its 200-day moving average price is $5.44.

Hedge Funds Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC bought a new stake in Briacell Therap (NASDAQ:BCTX – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on BCTX. Wall Street Zen upgraded shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Check Out Our Latest Report on Briacell Therap

Briacell Therap Company Profile

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.